RBOT Stock Risk & Deep Value Analysis
Vicarious Surgical Inc
DVR Score
out of 10
What You Need to Know About RBOT Stock
We analyzed Vicarious Surgical Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran RBOT through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
RBOT Risk Analysis & Red Flags
Risk Matrix
Overall
Aggressive
Financial
High
Market
High
Competitive
High
Execution
High
Regulatory
High
Upcoming Risk Events
- 📅
Failure to secure adequate funding leading to liquidity crisis
- 📅
Further delays in system development or regulatory approval
- 📅
Inability to meet Nasdaq re-listing requirements
- 📅
Significant further share dilution from capital raises
Unlock RBOT Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Vicarious Surgical holds a disruptive vision for humanoid-like robotic surgery in a massive TAM, potentially offering a significant competitive advantage. While current financial health is critical due to recent delisting from NYSE, short cash runway, and ongoing losses, management's efforts to reduce cash burn and pursue Nasdaq re-listing offer a speculative path to recovery. If the company successfully secures immediate funding, re-lists on Nasdaq, and executes on its system design freeze by end-2026, it could present an extreme high-risk, high-reward opportunity from its current depressed valuation.
Is RBOT Stock Undervalued?
Unlock the full AI analysis for RBOT
Get the complete DVR score, risk analysis, and more
RBOT Price Targets & Strategy
12-Month Target
$3.00
Bull Case
$7.00
Bear Case
$0.20
Valuation Basis
Based on a partial recovery from delisting, successful (re)listing on Nasdaq, and initial execution of 2026 milestones, moving towards the provided analyst fair value estimate of $5.
Entry Strategy
Highly speculative entry around current levels ($1.00-$1.20) only for aggressive investors comfortable with extreme risk. Given no clear support levels on OTC, dollar-cost averaging in small increments if a clear recovery path emerges.
Exit Strategy
Take profit on significant positive news, especially any successful capital raise or Nasdaq re-listing announcement, targeting initial exit at $3.00, partial exit at $5.00. Implement a stop-loss order below recent lows, e.g., $0.80, given the high downside risk.
Portfolio Allocation
0-1% for highly aggressive risk tolerance only. Not recommended for conservative or moderate portfolios.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is RBOT Financially Healthy?
Valuation
P/E Ratio
-0.06
Forward P/E
12.61
Balance Sheet
Total Debt
$525,000
Cash & Equivalents
$7.79M
Does RBOT Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
2 Identified
The moat, derived from its innovative technology and IP, has the potential to be durable if the company successfully navigates commercialization, regulatory hurdles, and secures market adoption. However, it is currently in a pre-commercialization phase, and its durability is untested.
Moat Erosion Risks
- •Rapid advancements by larger, well-funded competitors in surgical robotics
- •Failure to secure further foundational IP or defend existing patents effectively
- •Long and expensive regulatory approval process for novel medical devices
RBOT Competitive Moat Analysis
Sign up to see competitive advantages
RBOT Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bearish (due to NYSE delisting, retail investor confidence likely low, offset by a subset of hopeful investors given cost reductions and Nasdaq intent).
Institutional Sentiment
Negative (delisting from NYSE and lack of analyst coverage, no institutional ownership data points to minimal current interest).
Insider Activity (Form 4)
No specific Form 4 filings reported for the last 90 days (January 23 to March 23, 2026), indicating no significant insider buying or selling activity during this period.
Options Flow
Normal options activity (no specific unusual activity reported in the real-time market intelligence).
Earnings Intelligence
Next Earnings
Estimated November 11, 2025 (Q3 2025, after market close). NOTE: This date is inconsistent with Q4 2025 having been reported on March 9, 2026. The next actual earnings report should be for Q1 2026.
Surprise Probability
High (given the previous Q4 2025 miss and ongoing financial challenges, there's a high probability of missing future consensus estimates, especially for Q1 2026).
Historical Earnings Pattern
Based on Q4 2025 miss, the stock has shown negative reaction to earnings misses and has generally been on a downtrend due to financial concerns and development delays. Likely to be highly sensitive to any news regarding cash and Nasdaq re-listing.
Key Metrics to Watch
Competitive Position
Top Competitor
ISRG
Market Share Trend
Not applicable; company is pre-revenue and pre-commercialization. Focus is on product development and market entry.
Valuation vs Peers
Valuation metrics are largely unavailable for RBOT, making direct peer comparison challenging. However, given its pre-revenue status, delisting, and critical financial position, it likely trades at a significant discount to established, profitable peers like Intuitive Surgical when considering standard metrics, but its current market cap is extremely low in absolute terms.
Competitive Advantages
- •Differentiated humanoid-like robotic technology for minimally invasive surgery
- •Potential for single-incision surgical approach, reducing patient trauma
- •Extensive patent portfolio in surgical robotics and associated technologies
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive RBOT Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings report (expected to provide update on cash burn and runway)
- •Application to OTCQB and subsequent upgrade
- •Successful approval and execution of reverse stock split
- •Announcement of a new capital raise
Medium-Term (6-18 months)
- •Successful re-listing on Nasdaq
- •System design freeze by end-2026
- •Announcement of early strategic partnerships or collaborations
Long-Term (18+ months)
- •Submission for regulatory approval (e.g., FDA) for surgical robot
- •First commercial product launch and initial sales
- •Significant market penetration in the surgical robotics sector
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for RBOT?
- ✓
Successful capital raise with acceptable dilution terms (critical for survival)
- ✓
Official announcement of Nasdaq re-listing approval and effective date of reverse stock split
- ✓
Achieving the system design freeze milestone by end-2026 without further delays
- ✓
Any positive updates on pre-clinical or clinical trials for their robotic system
Bull Case Analysis
See what could go right with Premium
Competing with RBOT
See how Vicarious Surgical Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Vicarious Surgical Inc RBOT | — | 2.2 | -0.1 | — | 0.0% | 0.0% | |
Intuitive Surgical Inc ISRG | $201.3B | 3.0 | 74.1 | — | — | — | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Vicarious Surgical Inc (RBOT)?
As of March 23, 2026, Vicarious Surgical Inc has a DVR Score of 2.2 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the risk level for RBOT stock?
Our analysis rates Vicarious Surgical Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of RBOT?
Vicarious Surgical Inc currently has a price-to-earnings (P/E) ratio of -0.1. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Vicarious Surgical Inc's revenue growing?
Vicarious Surgical Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is RBOT stock profitable?
Vicarious Surgical Inc has a profit margin of 0.0%. The company is currently unprofitable.
How often is the RBOT DVR analysis updated?
Our AI-powered analysis of Vicarious Surgical Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 23, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for RBOT (Vicarious Surgical Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.